Biogen News and Research

RSS
Multiple sclerosis drug Tysabri could be back on the market later in the year

Multiple sclerosis drug Tysabri could be back on the market later in the year

Radioimmunotherapy streamlines non-Hodgkin's lymphoma treatment

Radioimmunotherapy streamlines non-Hodgkin's lymphoma treatment

Increased scrutiny of new multiple sclerosis-fighting drugs after Tysabri withdrawal

Increased scrutiny of new multiple sclerosis-fighting drugs after Tysabri withdrawal

New MS drug withdrawn from the market

New MS drug withdrawn from the market

Australian biotech, Bionomics acquires central nervous system (CNS) business

Australian biotech, Bionomics acquires central nervous system (CNS) business

GlaxoSmithKline acquires full marketing and development rights for BEXXAR worldwide

GlaxoSmithKline acquires full marketing and development rights for BEXXAR worldwide

FDA approval of Tysabri, for the treatment of multiple sclerosis

FDA approval of Tysabri, for the treatment of multiple sclerosis

Results from study of Rituxan in rheumatoid arthritis show promise

Results from study of Rituxan in rheumatoid arthritis show promise

Scientists have sped up a common jumping gene found in the human genome

Scientists have sped up a common jumping gene found in the human genome

The number of antibody-based medicines will climb dramatically

The number of antibody-based medicines will climb dramatically

FDA approves new drug Enbrel for psoriasis

FDA approves new drug Enbrel for psoriasis

Study of an oral fumarate shows improvement in psoriasis

Study of an oral fumarate shows improvement in psoriasis